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The prosurvival activity of phosphoinositide 3 kinase (PI3K)/Akt (also known as protein kinase B, PKB) pathway has been investi-
gated in great detail in human physiology and disease. Accumulating evidence is emerging that this signaling axis also actively 
engages with the migratory process in motile cells, including metastatic cancer cells. Interference with the role of PI3K/Akt–medi-
ated cell motility impairs cellular development and attenuates malignant progression of cancer metastasis. Because metastasis is 
responsible for 90% of mortality in cancer patients, the acceleration of cancer cell spreading observed in association with hyper-
activation of the PI3K pathway, triggered for example by chemotherapy/radiotherapy in the clinic, has heightened awareness of 
the conflict between “good drugs” and unfavorable effects. Here, we discuss recent studies on PI3K/Akt–regulated cell motility in 
both physiological and pathological settings, with the aim of a better understanding of how activities of the PI3K/Akt axis initiate 
and transmit “migratory signals” that stimulate cell movement. We focus in particular on its direct influence on cell migration and 
invasion, epithelial-mesenchymal transition, and cancer metastasis.
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Membrane targeting is an initial step in the activation of a broad 
variety of signaling proteins during the development of multicel-
lular organisms. Acidic phospholipids that constitute about 11% 
of total lipid in the plasma membrane (1) act as the major signaling 
messengers of basic cellular processes such as migration, differ-
entiation, mitosis, and polarity. Phosphatidylinositol (4,5)-bis-
phosphate (PIP2) and phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3), two phosphoinositides that make up only 1% of mem-
brane phospholipid molecules, have been shown to have a critical 
influence collaboratively on the activity of distinct signaling cas-
cades. PI3K, one of an evolutionarily conserved intracellular lipid 
kinase family that converts PIP2 to PIP3, and the phosphatase and 
tensin homolog that reverses this process, constitute a functional 
switch that results in the precise temporal and spatial regulation 
of signaling. Lipid-mediated membrane recruitment arises by the 
specific interaction of lipid-binding domains and target proteins 
with a remarkable affinity. The pleckstrin homology domain, one 
of approximately 11 investigated lipid-binding motifs, is com-
posed of approximately 100 amino acids and occurs in a broad 
range of proteins that associate functionally with the intracellular 
membrane. Upon stimulation, pleckstrin homology domain–con-
taining proteins such as Akt, phosphoinositide-dependent kinase 1 
(PDK1), and phospholipase C (PLC) recognize and bind to newly 
generated and enriched PIP3, resulting in its transient membrane 
relocalization and consequent activation. For example, when Akt 
associates with the membrane, it is rapidly phosphorylated by 
PDK1 on threonine 308 (T308) and by the mammalian target 
of rapamycin complex 2 (mTORC2) on serine 473 (S473), which 
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results in maximal Akt activation in the mediation of downstream 
signaling. Indeed, although still not fully understood, the PI3K/
Akt/mTOR signaling axis has emerged as a pivotal node of many 
signaling cascades in human physiology and pathology. Genetic 
depletion of Akt isoforms or epigenetic inhibition of its activity 
results in functional abnormalities in mice. In the clinic, diabetes 
and cancer are tightly associated with aberrant Akt activity, which 
has attracted great attention in attempts to develop specific inhibi-
tors as therapy for these diseases. Given that the contribution of 
this signaling axis to cell proliferation and survival has already 
been widely discussed (2–4), in this review we discuss recent dis-
coveries that highlight the influence of PI3K/Akt/mTOR signal-
ing (Figure 1) on cell migration and invasion, focusing particularly 
on its direct involvement in the modulation of cytoskeleton.
Pi3K/Akt–Regulated Cell Migration 
in the Developing embryo
Defined by distinctions in morphology, migratory behavior, and 
molecular signatures, epithelial and mesenchymal cells constitute 
the two major cell types in metazoa. Their interconversion 
(epithelial-mesenchymal transformation, EMT) is a frequent event 
during embryo development and is a fundamental mechanism in 
the formation of adult organs and tissues. Unlike epithelial cells, 
which are organized into adherent sheets restricted by intercellular 
junctions, mesenchymal cells are characterized by their irregular 
shape, disrupted cell–cell contact, and high motility. During 
gastrulation of the early embryo, the first EMT results in the 
organization of the mesoderm (5). Several studies in different 
model organisms have provided evidence that activated PI3K/Akt 
signaling contributes to EMT-driven mesoderm formation. At the 
onset of zebrafish gastrulation, activated Akt colocalizes with actin 
bundles at the leading edge of mesendodermal cells that undergo 
an EMT during internalization (6). In response to signaling 
attractants, such as platelet-derived growth factor (PDGF), the 
mesoderm cells rapidly orientate and migrate to the signal source, 
where they exhibit elevated membrane protrusive potential. 
Treating migrating mesendodermal cells with a PI3K/Akt inhibitor 
suppresses the formation of membrane protrusive structures, 
including filopods and pseudopods, and reduces the asymmetrical 
distribution of Akt at the leading edge. This is accompanied by 
strongly reduced cell migration, which indicates an influence of 
PI3K/Akt signaling on cell polarity and motility in the gastrula 
embryo. Interestingly, although migration speed is markedly 
reduced, inhibition of the PI3K/Akt pathway does not influence 
the direction of cell migration. Analysis of PDGF signaling in 
Figure 1. Classical phosphoinositide 3 kinase (PI3K)/Akt signaling pathway. Upon activation by growth factor receptor kinases (GFRKs), as well 
as integrin, G-protein-coupled receptor (GPCR), and cytokine receptor (CR) signaling, PI3K is phospho-activated to convert phosphatidylinosi-
tol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which triggers Akt membrane targeting. Maximal activity of Akt 
requires threonine 308 (T308) phosphorylation mediated by phosphoinositide-dependent kinase 1 (PDK1) and serine 473 (S473) phosphorylation 
by mTOR complex 2 (mTORC2) or DNA-dependent protein kinase (DNAPK). Activated Akt phosphorylates a number of substrates that perform dif-
ferent functions in a variety of cellular conditions, including several cytoskeleton-regulating proteins and epithelial-mesenchymal transformation 
(EMT)–activating proteins that specifically regulate cell motility. To be noted, other pathways that crosstalk with PI3K/Akt are capable of regulating 
cell migration and invasion in a PI3K/Akt independent manner. These aspects, however, are neither illustrated in this figure, nor discussed in the 
text. MAPK = mitogen-activated protein kinase.
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the early chick embryo, especially during gastrulation, indicated 
that induced expression of N-cadherin on the plasma membrane 
of mesoderm cells, particularly enriched in cellular protrusions, is 
probably a key determinant of cell migration. Interference with 
PDGF signaling suppressed N-cadherin expression, inhibited Akt 
phosphorylation, and associated with decreased cell migration, 
thus highlighting an active signaling route from PDGF to PI3K/
Akt and N-cadherin during cell migration. Further studies 
confirmed that inhibition of PI3K/Akt, when PDGF signaling is 
maintained intact, also inhibits N-cadherin expression, suggesting 
that PDGF-mediated signaling drives cell migration, at least in 
part, by upregulation of N-cadherin and activation of the PI3K/
Akt pathway, thus defining this signaling axis as a central node 
during mesoderm cell migration (7). Consistent with these data, 
cyclo-oxygenase-1–mediated activation of prostaglandin E2/G-
protein-coupled EP4 receptor signaling axis elevated the velocity 
of mesodermal cell migration through the activation of the PI3K/
Akt signaling node (8). Taken together, these data demonstrate that 
PI3K/Akt activity is crucial to the promotion of mesodermal cell 
migration during vertebrate gastrulation.
Given the fact that the intracellular PI3K/Akt signalosome 
is at the crossroads of many membrane-bound receptor kinase 
signaling pathways, disturbance of its activity causes severe defects 
during embryogenesis. Indeed, dysregulation of PI3K/Akt activity 
either by upregulation/downregulation of the phosphatase and 
tensin homolog or by the overexpression of constitutively active 
Akt results in abnormal gastrulation (9–11). However, dependence 
of active Akt proteins on cell migration during the whole course 
of embryonic development is not yet understood, particularly at 
gastrulation, when EMT-associated cell migration is critical for 
developing embryos (12,13). Because Akt knockout mice display 
severely impaired embryo development, future studies should 
investigate in detail whether mesodermal formation is affected in 
Akt knockout mice.
Activation of Pi3K/Akt at the Leading edge 
of the Plasma Membrane of Postnatal 
Motile Cells
Increased cell motility is often reflected in enhanced dynamic 
remodeling of the cytoskeleton, characterized by distinct changes 
in cell morphology and polarity and is associated with differentially 
activated biochemical signaling on the membrane. Cell migra-
tion has been suggested to follow two major patterns: collective 
and individual (14). In collective migration, intercellular coupling 
forces remain intact during cell movement, and thus migrating cells 
exhibit cohesive migration as an entity. In contrast, in single-cell 
(amoeboid, mesenchymal) migration, cells lose cell–cell contact 
and generate moving force individually (15). Both migration modes 
of animal cells display high diversity. There is emerging evidence 
that border cells determine directed group migration in response 
to the surrounding environment, in particular to chemotactic cues 
and invading pathogens. Interestingly, in a recent study using live-
imaging microscopy, single cells were seen to promote a directional 
collective movement by transducing extrinsic signaling cues to 
the group (16), indicating that mutual interdependence of distinct 
migration behavior is the basis of an overall migratory mechanism.
Akt family members are broadly expressed in most cell types, 
and a basal activity is maintained in cultured cells. Less-motile epi-
thelial cells that display apical–basal polarity often display an even 
distribution of basal level of phosphorylated Akt on the plasma 
membrane, overlapping with cortical actin filaments (Figure 2A). 
This epithelial integrity is disrupted by the introduction of migra-
tion-promoting factors such as Twist, a master regulator of EMT 
(17), which results in solitary cells by the cleavage of intercellular 
junctions and a transition from apical–basal to front–rear polarity 
and elevated cell motility. In these conditions, phosphorylated Akt 
is substantially enriched on unique membrane structures, colocal-
izing with strengthened actin bundles (Figure 2B). Indeed, Twist-
expressing cells undergo EMT and trigger the paracrine signaling 
loop. For example, when normal NMuMG epithelial cells were 
incubated with the medium that was used to culture MDCK/
Twist1 cells, NMuMG cells started to undergo EMT within 6 
hours (Figure 2C, ii). In particular, only those cells at the edge show 
remarkably activated Akt and vimentin, which are colocalized on 
membrane protrusions. This invasive behavior is also frequently 
observed in many types of highly migratory cancer cells that often 
cause metastases (Figure  2D). Activated Akt at the leading edge 
participates in the regulation of cell polarity and reorganization of 
the cytoskeleton and mediates contraction of the cellular body, thus 
facilitating directed migration of the cell.
Transition of cell polarity from apical–basal to front–rear axis, 
usually termed EMT, is a predominant characteristic of cell migra-
tion induced by extracellular stimuli such as growth factors. This 
leads to local asymmetric redistribution of signaling molecules over 
the plasma membrane, often associated with specific reprogram-
ming of gene expression and/or repression that impacts on inter-
cellular and cell–substratum interactions during migration. The 
first evidence of Akt involvement in the regulation of polarity plas-
ticity came from studies on Dictyostelium, in which the Akt pro-
tein is an evolutionarily conserved homolog of mammalian Akt1. In 
response to cAMP stimulation, Akt was recruited to the membrane 
and activated, which led to the direct phosphorylation on threonine 
579 (T579) and activation of PAKa, a key regulator of cell migra-
tion belonging to the p21-activated serine/threonine kinase family 
(18,19).Inhibition of T579 phosphorylation dramatically decreased 
cell migration velocity, probably because of disrupted myosin 2 
assembly and impaired polarity (20). Although this phosphoryla-
tion site is not present in mammalian PAK1, it has been shown that 
another site (serine 21) is phosphorylated by Akt, which is impor-
tant for its binding to the noncatalytic region of tyrosine kinase 
adaptor protein (Nck) and the promotion of directed cell migra-
tion induced by growth factors (21). Nevertheless, a recent report 
pointed out that PAK1 could also mediate feed-forward signals, 
facilitating membrane targeting and the activation of Akt proteins 
through direct interaction but in a catalytic activity–independ-
ent manner (22). Interestingly, selective interference with Akt1 by 
expression of its kinase-dead form or by knockdown considerably 
inhibited PAK1-promoted cell migratory and invasive capacity, 
suggesting that Akt is an essential downstream effector of PAK1 in 
stimulating cell motility. Consistently, another earlier report also 
showed that a dominant negative mutation of Akt efficiently atten-
uated PDGF/Rac/Cdc42–promoted cell migration in mammalian 
fibroblasts (23). Although these data did not suggest a mechanism 
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by which PAK1/Akt complex formation is regulated, the concept 
of Akt proteins and direct regulation of cell motility along the PAK 
signaling pathway was established.
Akt-Regulated Cytoskeleton-Related 
Proteins
Whatever signaling pathways are activated, cell motility is driven 
ultimately by adapted cytoskeletal remodeling. Extensive studies 
have focused on how dynamic polymerization and stabilization of 
intracellular filaments regulates cell migration (24,25). The con-
cept of a migration cycle (26–28) simplified this complex and het-
erogeneous process into four fundamental steps: 1) initiation and 
polarization, 2) formation of membrane protrusions at the leading 
edge and membrane retraction at the trailing edge, 3)  contrac-
tion of the cell body, and 4) re-establishment of adhesion between 
cell and substratum. Several key components closely associ-
ated with the cellular filaments that are important for cytoskel-
eton dynamics have been shown to be activated by Akt-mediated 
phosphorylation.
Figure 2. Phosphorylated Akt colocalizes with highly polymerized actin at membrane protrusions in motile cells. A) MDCK exhibits classical epi-
thelial phenotype. B) Upon ectopically introducing Twist, the intercellular contact is disrupted, multiple membrane protrusion forms and F-actin is 
specifically accumulated and colocalizes with increased Akt phosphorylation. C) Epithelial cells NMuMG start to undergo epithelial-mesenchymal 
transformation when incubated with conditional medium from MDCK/Twist1 cell culture. D) This morphological change is remarkably observed in 
many types of invasive cancer cell such as metastatic melanoma cell A375p/MC2.
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Akt and Actin
Vascular endothelial cell migration is a critical process in 
angiogenesis. Microvascular endothelial cells show enhanced 
actin polymerization upon stimulation by vascular endothelial 
growth factor (VEGF), associated with elevated motility and Akt 
activation. Inhibition of Akt activity by expression of a kinase-
dead mutant abrogated actin bundle formation and blocked cell 
locomotion. This effect was enhanced when myristylated Akt was 
expressed (29), indicating that Akt is a critical mediator of VEGF-
induced endothelial cell migration through actin reorganization. 
Similarly, interfering with Akt activity in embryonic fibroblasts 
effectively blocked PI3K-transduced migratory signals (30). In 
neutrophils, activation of G-protein-coupled chemokine receptors 
leads to F-actin polymerization and cytoskeleton contraction as 
a result of PIP3 signaling. This rearrangement pattern of actin 
ensures pseudopod extension in human neutrophils during chemo-
attractant stimulation, which is dependent on Akt activity (31). In 
breast cancer cells, enhanced cell migration and invasion is often 
associated with increased filopodia production, which occurs in an 
active Akt-dependent manner. Treating the human breast cancer 
cell line BT549 with the small-molecule allosteric inhibitor API-
2, which specifically targets only Akt proteins, blocked filopodia 
formation (32). This was also seen in integrin-like kinase–induced 
cellular actin rearrangement and motility, for which Akt activity 
was indispensable (33).
Taken together, these observations support the model that 
Akt activation potentially influences cell motility through direct 
modulation of actin. Interestingly, further studies have provided 
evidence that actin preferentially binds to phosphorylated Akt at 
pseudopodia with enhanced bundles (34,35). As to the question of 
whether actin is a substrate of Akt, one study showed that actin 
is markedly concentrated in an immunocomplex containing phos-
phorylated Akt, 14-fold higher than in a corresponding complex 
containing inactive Akt (36). It was demonstrated further that actin 
can be phosphorylated by Akt (37) and that cortical remodeling of 
actin associated with cell migration is strongly dependent on Akt 
proteins.
Akt and Actin-Tethering Molecules
Actin polymerization is a highly dynamic process. Actin-rich 
membrane structures frequently observed in highly motile cells, 
such as filopodia, pseudopodia and invadopodia, need to be stra-
tegically stabilized to function properly. This stabilization usually 
results from the activity of actin-associated proteins that pre-
vent the degradation of newly formed actin filaments. The Akt 
phosphorylation enhancer (APE), also termed girders of actin 
filaments (girdin), is an actin-binding protein that maintains the 
integrity of actin filaments, particularly the actin meshwork at the 
leading edge of migrating cells. Depletion of APE/girdin dramati-
cally destabilizes actin bundles, resulting in ablation of stress fib-
ers and cortical actin structure. This leads to loss of directional 
migratory capacity and illustrates the crucial activity of APE in 
the coordinated regulation of cell migration. Notably, Enomoto 
and colleagues demonstrated that APE/girdin is phosphorylated 
by Akt on serine 1416 (S1416) (38). In response to an extracel-
lular stimulus such as EGF, S1416 phosphorylation triggers the 
rapid translocation of APE/girdin from the junctions between 
actin filaments to the leading edge, colocalized with phosphoryl-
ated Akt. This phosphorylation pattern seems to be crucial for 
cell migration, as expression of a nonphosphorylatable mutant 
S1416A or knocking down Akt-attenuated cell movement. Indeed, 
recent observations in the clinic that APE/girdin is overexpressed 
in malignant human cancers and that this is associated with 
metastatic potential (39–41) further demonstrated that APE is a 
stringent mediator able to signal Akt-controlled cell motility in 
both physiological and pathological settings. Curiously, it was 
reported that Akt phosphorylates kank, a kidney ankyrin repeat-
containing protein, which subsequently led to negative regulation 
of the assembly of stress fibers and RhoA activation, thus block-
ing cell migration (42). It is not yet clear whether this reflects a 
negative feedback signaling loop related to the cessation of cell 
movement. A further actin-associated cross-linker protein, filamin 
A (43,44), was shown to be phosphorylated by Akt on serine 2152 
(45,46), mediating caveolin-1–driven cancer cell migration along 
the IGF pathway. Moreover, the sodium–hydrogen exchanger iso-
form 1 (NHE1) was also shown to be a key mediator of stress 
fiber disassembly induced by insulin and PDGF, and this activity 
required Akt-directed phosphorylation on serine 648 (S648) (47). 
S648 phosphorylation of NHE1 was proposed to be critical for 
the growth factor–initiated cytoskeletal reorganization that favors 
cell migration and invasion, at least in part through the disas-
sembly of cellular filamentous structures. Although it is not clear 
mechanistically how S648 phosphorylation initiates cell motility, 
the involvement of NHE1 in the promotion of cell migration by 
modulation of the cytoskeleton has been demonstrated in differ-
ent cell types (48–51). Recently, NHE1 was discovered to interact 
with cortactin, an actin regulatory protein that promotes invado-
podium formation and maturation in many cancer cells. NHE1 
is selectively recruited to invadopodia in invasive breast cancer 
cells (52), where it locally regulates pH-dependent interactions 
of promigratory proteins, stabilizing newly formed actin-rich 
invadopodia. This action favors invadopodial elongation of cancer 
cells and, thus, their dissemination from the primary site to distant 
organs. Whether NHE1 recruitment is dependent on S648 phos-
phorylation is a crucial question for further studies.
Akt and F-Actin Assembly
Toker and colleagues have shown another aspect of Akt activa-
tion that affects cell motility negatively (53). The actin-binding 
protein palladin crosslinks and scaffolds other actin-associated 
proteins, maintaining the integrity of the actin meshwork in 
cells. Interestingly, palladin is specifically phosphorylated by Akt1 
on serine 507 (S507), which leads to disruption of F-actin bun-
dles. This Akt-dependent inhibition phenotype mediated by its 
isoform-specific substrate was observed in breast cancer cells in 
which expression of Akt1 suppressed cell movement. This is con-
sistent to some extent with further observations that the ratio of 
Akt isoforms determines cell fate. Indeed, unlike the antimigratory 
activity of palladin mediated by Akt1 phosphorylation, Akt2 con-
tributes to palladin stability independent of S507 phosphorylation 
(54). Similarly, Akt1 also phosphorylates and thus destabilizes the 
tuberous sclerosis complex 2 (TSC2), a Rho GTPase regulator that 
influences cell migration, which leads to an attenuated migratory 
phenotype due to impaired F-actin assembly (55). The opposing 
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roles of Akt isoforms in the regulation of cell motility will be dis-
cussed later.
Akt and Intermediate Filaments
The role of intermediate filaments in cell motility has been studied 
extensively (56,57). The type 3 filamentous protein vimentin is the 
most abundant cellular intermediate protein that maintains nor-
mal cell and tissue integrity. Based on broad investigations, vimen-
tin appears to be one of the most important of the factors that are 
substantially upregulated when cells become highly motile, par-
ticularly during EMT, and therefore promote migration and inva-
sion of different cell types, both in physiological and pathological 
conditions such as cancer. Although it possesses a nonclassical 
motif, vimentin is phosphorylated by Akt1 on serine 39 (S39) (58). 
This phosphorylation pattern protects vimentin from degradation 
and thereby regulates cancer cell invasion in aggressive mesen-
chymal-originated soft-tissue sarcoma, as was demonstrated using 
nonphosphorylatable or phospho-mimicking mutants. Clearly, it 
is important to know whether vimentin phosphorylation is also 
part of a general mechanism in other cancer types, such as breast 
cancer, in which vimentin is strongly expressed in lung metasta-
ses and is considered to be a promising target in cancer therapy 
(59,60).
However, the precise mechanisms how some of the Akt sub-
strates regulate cell motility are still unclear. For example, two inde-
pendent studies reported in 2009 that a component of E3 ligase, 
S-phase kinase-associated protein 2 (Skp2), was phosphorylated 
by Akt (61,62). Akt-mediated phosphorylation on serine 72 acti-
vated Skp2-dependent E3 ligase activity and promoted cell migra-
tion through maintaining Skp2 in cytoplasm. Depletion of Skp2 in 
MEF cells strongly inhibited cell migration, a phenotype that was 
rescued by re-expression of a potential phospho-mimicking mutant 
Skp2_S72D but not Skp2_S72A mutant (61), indicating a role of 
S72 phosphorylation in regulation of cell motility. Although the 
mechanism needs further investigation, aberrant overexpression 
of Skp2 and its cytoplasmic localization in highly invasive human 
cancer cells indirectly supports the experimental observations. 
Nevertheless, uncertainties have been reported (63–65). Regardless 
of the variety of models applied in the studies, the global effects of 
S72 phosphorylation need to be revisited.
As discussed above, remodeling of the cell skeleton is the direct 
precursor of cell migration. Migration potential arises because of 
a synergistic effect of all the three basic elements—filamentous 
actin, microtubule, and intermediate filament vimentin. In addi-
tion, Akt regulates microtubule dynamics at its plus end through 
Akt/GSK3β axis-dependent activation of microtubule binding 
protein adenomatous polyposis coli, thus promoting cell migration 
(66–69). Cooperative interactions between intracellular filament-
associated proteins regulate cell motility through the dynamic 
assembly of cellular protrusions, focal adhesions, and retractions 
in response to extracellular stimuli. The specific impact of Akt on 
the activities of these proteins provides unambiguous evidence that 
Akt may directly influence cell movement (Figure 3), in addition to 
its well-known prosurvival activity. This aspect of metastatic tumor 
progression is particularly important because understanding the 
mechanism of Akt-promoted metastasis should help in the search 
for more specific drug targets for halting metastasis.
Akt-Regulated Cell Motility Through 
signaling Crosstalk
Akt and VEGFR/eNOS Signaling
In addition to targeting cytoskeletal proteins by phosphoryla-
tion, Akt also interacts with other promigratory proteins, thus 
Figure 3. Akt is activated through upstream signalosomes and transduces migratory signals through phospho-regulation of its substrates that are 
required for cell movement.
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mediating crosstalk between affiliated signaling axes. Akt binds 
and phosphorylates endothelial nitric oxide (NO) synthase 
(eNOS) on serine 1177 (S1177) (70). S1177 phosphorylation 
enhances eNOS catalytic activity and leads to NO produc-
tion, which is necessary for endothelial cell migration (71,72). 
Consistent with the activity of NO in angiogenesis, VEGFR 
activation induces NO production, vasculature formation, and 
cell migration. Indeed, VEGFR/eNOS pathway–regulated cell 
migration is dependent on Akt-mediated S1177 phosphorylation 
(73). Dephosphorylation of S1177 attenuates migratory potential 
(74), demonstrating the importance of the PI3K/Akt signaling 
axis in crosstalk with the VEGFR/eNOS pathway in the regula-
tion of endothelial cell motility (75). This appears to increase in 
statistical significance, as accumulating observations have pointed 
out the importance of NO in pathological situations, particularly 
in malignant tumor development (76,77).
In parallel, VEGFR signaling often interacts with the 
G-protein-coupled receptor, sphingosine-1-phosphate (S1P) 
receptor 1 (S1PR1), also known as endothelial differentiation 
gene 1 (EDG-1). S1P is a platelet-derived sphingolipid that binds 
to EDG-1 and activates eNOS. S1P/EDG-1 activation leads to 
VEGFR phospho-activation mediated through activated Src 
kinase, which subsequently activates the PI3K/Akt/eNOS axis 
(78). Notably, EDG-1 activation can be further enhanced by Akt-
mediated phosphorylation on threonine 236 (T236), promoting 
cortical actin assembly, angiogenesis, and directed cell migration 
(79). These data define Akt as the central node in looping signal-
ing routes between VEGFR and S1P/EDG-1, actively regulating 
cell motility.
Akt and Ephrin Receptor Tyrosine Kinase Signaling
Ephrin receptor tyrosine kinases (Eph) are probably the larg-
est tyrosine kinase family, including about 14 receptors and 8 
ligands. Eph signaling is rather complex and paradoxical: it was 
reported to be both pro- and antitumorigenic, most likely in 
a cellular context–dependent manner (80). One receptor fam-
ily member, EphA2, was shown to inhibit cancer cell growth 
through a receptor-ligand signaling route, but promote cancer 
cell invasion through intracellular signaling crosstalk, for exam-
ple with PI3K/Akt, independent of ligand binding. Interestingly, 
in the case of ligand binding–independent activation, activated 
Akt physically associates with and phosphorylates EphA2 on 
serine 897 (S897). In human brain cancer cells, S897 phos-
phorylation was shown to be responsible for Akt-promoted 
cell migration and invasion due to effects on dendritic actin 
cytoskeleton assembly and lamellipodia formation at the leading 
edge of migrating cells (81). Consistent with a pro-oncogenic 
role of EphA2, the S897 phosphorylation level was shown to 
positively associate with malignancy in human glioma samples, 
indicating that Akt/EphA2 plays an essential role in brain tumor 
progression.
Akt, ACAP1/ARF6, and Integrin Recycling
Integrin recycling directed by small GTPases, particularly Rab fam-
ily members, has been increasingly reported (82–84). At present, it 
is well established that membrane redistribution of integrin upon 
extracellular signaling is an important mediator of cell movement. 
The arf-GAP, with a coiled-coil, ANK repeat, and pleckstrin 
homology domain–containing protein 1 (ACAP1), is a GTPase-
activating protein (GAP) for ADP ribosylation factor 6 (ARF6) 
and has been shown to participate in integrin β1 recycling. In the 
investigations of whether Akt is able to phosphorylate ACAP1 on 
serine 554 (S554), which is required for its interaction with integrin 
β1 in response to serum stimulation, specific knockdown of Akt or 
the application of an Akt inhibitor abolished S554 phosphoryla-
tion and blocked induced integrin β1 recycling and, consequently, 
cell migration (85). Another GAP protein, RhoGAP22, was also 
reported to regulate cytoskeleton remodeling upon phosphoryla-
tion on serine 16 by activated Akt (86), further illustrating a func-
tional involvement of Akt signaling in small GTPase-modulated 
cell motility.
Indeed, Akt-dependent cell migration in association with many 
other signaling axes such as GTPases has also been reported but 
by as-yet-unknown mechanisms (22,23). Given that Akt is at a cen-
tral signaling node, Akt activation–promoted cell motility through 
transducing signals from upstream signalosomes is apparently a 
global event.
Akt and eMT inducers
EMT is an embryonic program important for organogenesis in 
normal development, but its dysfunction can favor the survival 
and dissemination of cancer cells (87). Several transcription fac-
tors have been discovered that can initiate and maintain this pro-
cess, including Snail, Twist, and Zeb. Although these transcription 
factors are apparently deregulated in many types of invasive can-
cer, the precise signaling mechanisms by which they are normally 
regulated at the molecular level are poorly understood. Evidence 
is emerging of a connection between Akt and the EMT-inducing 
transcription factor signaling axis. The first observation was that 
Snail is phosphorylated by GSK3β in normal epithelial cells. Snail 
is a rather unstable protein and hardly detectable in normal cells. 
Its expression in epithelial cells strongly induces morphologi-
cal change associated with increased migratory capacity. Further 
experimental data showed that Snail, when phosphorylated by 
GSK3β, undergoes continuous degradation (88,89). However, 
when GSK3β is phosphorylated by hyperactivated Akt, which leads 
to its inactivation, the Snail protein is stabilized and activates the 
EMT program. This is probably consistent with the situation in 
invasive cancers in which Snail is overexpressed, positively associ-
ated with high Akt phosphorylation but negatively with GSK3β 
expression. Akt-promoted activation of Snail1 was also observed 
when YB-1 was phosphorylated by Akt and subsequently translo-
cated into the nucleus (90). Moreover, upregulated Snail1 could, 
in turn, enhance Akt activity (91). This signaling loop apparently 
favors escape of cancer cells from oncogene-induced senescence 
and their re-establishment in distant organs. A direct interaction 
was reported recently when Akt2 was shown to stabilize Snail1 bind-
ing to the CDH1 (which encodes E-cadherin) promoter through 
direct protein–protein interaction (92). It is not yet clear whether 
Akt2 mediates formation of a specific transcriptional complex that 
leads to inhibition of Snail-induced senescence gene expression 
but activation of proinvasive gene expression. However, a further 
EMT-inducer, Twist, was shown to bind directly to and specifically 
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activate Akt2 transcription in invasive breast cancer cells (93); 
inactivation of Akt downregulates Twist (68). Furthermore, Akt 
phosphorylates and activates Twist1, which results in increased Akt 
phosphorylation, at least in part because of enhanced TGFβ sign-
aling (94–96). Recent data also suggests that the polycomb group 
protein Bmi-1 is a downstream target of Twist1 and is indispensa-
ble for EMT and cancer metastasis (97). Interestingly, Akt directly 
phosphorylates Bmi-1 in human high-grade prostate tumors (98). 
Taken together, these results indicate an important interaction 
between Akt and EMT inducer–associated signaling (Figure  3). 
This synergistic interplay has crucial and unfortunate pathological 
effects: 1) it prevents stress-induced cell cycle arrest in cancer cells, 
2)  it promotes proinvasive/metastatic gene expression, and 3)  it 
maintains hyperactivation of PI3K/Akt signaling, which further 
enhances the antiapoptotic potential of cancer cells.
Akt isoforms and Differential Regulation 
of Cell Motility
Mammalian genome Akt encodes three isoforms, and studies of 
germ line depletion have revealed nonredundant activities of Akt 
isoforms in development. Akt1-depleted mice exhibit severe growth 
retardation and partial perinatal lethality, Akt2-depletion leads to a 
diabetic phenotype, and Akt3 knockout mice show defects in brain 
development (4). Although high Akt phosphorylation is known to 
drive malignant cancer progression, it is not easy to dissect any Akt 
isoform–specific roles in cancer because of their very high homol-
ogy and their shared substrates. Over the past 10 years, accumulat-
ing results from cultured cancer cells and mouse models have begun 
to reveal distinct roles for Akt1 and Akt2 in different cancer types.
Impacts of Akt1 in Maintenance of Primary Tumor 
Growth and Breast Cancer Cell Dissemination
Most studies on Akt1 and Akt2 in cancer are based on mouse 
mammary tumor virus (MMTV)–polyoma virus middle T antigen 
(PyMT) and MMTV–ErbB2 transgenic mice that exhibit metastatic 
phenotypes. Maroulakou and colleagues showed that genetic abla-
tion of Akt1 in both MMTV–PyMT and MMTV–ErbB2 mice sta-
tistically significantly inhibited transgene-driven tumor formation 
(99), led to increased apoptosis of tumor cells, and thus substantially 
delayed tumor growth. A similar effect was observed by Ju and col-
leagues in the same genetic background of the model animal (100). 
This was consistent with observations in MMTV–ErbB2 mice with 
constitutive Akt1 (myr-Akt1) or Akt1–T308D/S473D knock-in of 
accelerated primary tumor formation (101,102). In another mouse 
model expressing the MMTV–PyMTmut transgene that uncou-
ples the PI3K pathway, expression of Akt1–T308D/S473D rescued 
MMTV–PyMTmut-induced apoptosis, thus supporting tumor 
growth (103). Interestingly, expressing Akt1–T308D/S473D in 
MMTV–ErbB2 mice statistically significantly inhibited transgene-
promoted lung metastasis (102,104), but this was not apparent in 
MMTV–PyMTmut transgenic mice (103).
In addition to the transgenic models, studies in cultured cells 
and in xenograft models have offered further information. For 
example, Toker and colleagues showed that expression of Myr–Akt1 
or Akt1–T308D/S473D in breast cancer cell lines inhibited inva-
sive potential but, conversely, increased invasion upon knockdown 
of endogenous Akt1 (105,106). Bissell and colleagues showed 
decreased motility of breast cancer cells expressing activated Akt1 
due to decreased Rho GTPase activity (55). Downregulation of 
Akt1 strongly promoted EMT in a mammary epithelial cell line, 
indicating its antimigratory activity (107). These results established 
the anti-invasive influence of Akt1 in breast cancer. However, Akt1 
promotes cell motility and metastasis in other cell types and ani-
mal models of different cancer types. In a transgenic mouse model 
expressing a mutant thyroid hormone receptor (TRβPV/PV), abla-
tion of Akt1 inhibited metastasis of thyroid cancer (108,109). In 
Dictyostelium, Akt1-null mutant has reduced migratory potential 
toward the chemoattractant cAMP (110). Knockdown of Akt1 
in the colon cancer cell line HCT116 substantially reduced liver 
metastasis in a xenograft mouse model of colorectal cancer (111), 
and Akt1 knockout in MEF cells resulted in slower migration (112). 
Finally, introducing Akt1 into a transformed mouse mammary epi-
thelial cell line, COMMA-1D, elevated its motility in association 
with upregulation of MMP-2 (113). In addition, several studies 
have reported the proinvasive influence of Akt1 in other cancer 
types, such as pancreatic cancer (114), fibrosarcoma (115), soft-
tissue sarcoma (58), and ovarian cancer (116).
Impacts of Akt2 in Cell Motility and Cancer Metastasis
Unlike the profound influence of Akt1 on cell proliferation and 
primary tumor initiation and maintenance, Akt2 has advantages in 
promoting cell migration and invasion. Knocking in Akt2–T308D/
S473D in both MMTV–PyMTmut and MMTV–ErbB2 trans-
genic mice led to massive lung metastases with no impact on mam-
mary tumor development (104). In a xenograft model of colorectal 
cancer, knockdown of Akt2 in colon cancer cells KM20 inhibited 
liver metastasis; the converse was observed when Myr–Akt2 was 
expressed (117). Knockdown of Akt2 induced reversion of the EMT 
process in mammary epithelial cell lines (107). Activation of Akt2 
increased cell invasion and metastasis of breast and ovarian cancer 
cells through upregulated integrin signaling (118). Inactivation of 
Akt2 inhibited glioma cell invasion (119), and knockdown of Akt2, 
rather than Akt1, in the lung adenocarcinoma cell line A549 dra-
matically abolished its invasive potential (120). Interestingly, in 
contrast with Akt1, Akt2 inhibits MEF cell migration (112), indi-
cating that Akt1 and Akt2 differentially impact on cell motility in 
different cell types (Figure 4).
Conclusions
The PI3K/Akt pathway not only regulates cell proliferation and 
survival and increases protein synthesis and metabolism, but it is 
also actively involved in cancer metastasis, in particular in can-
cer cell motility. Because cancer metastasis is the major cause of 
death of cancer patients, preventing cancer cell movement would 
be beneficial in the clinic. Given the high sequence homology of 
Akt isoforms, it is surprising that each isoform has distinct activi-
ties in different contexts and they are not intercomplementary. 
This provokes the critical question of how individual Akt isoforms 
transduce specific signals. One way to answer this question would 
be to search for isoform-specific substrates, and recent studies have 
started to shed light in this direction. The finding that palladin, 
the actin-binding protein that regulates cell motility by tethering 
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F-actin bundles, is preferentially phosphorylated by Akt1 (121) 
indicated a molecular mechanism by which Akt1 directly inhibits 
epithelial cell motility. Interestingly, palladin is also associated with 
Akt2 in a phosphorylation-independent manner (122), giving rise 
to the important concept that the ratio of Akt1 and Akt2 may have 
a temporal and spatial influence on cell movement (123). A  fur-
ther cytoskeletal component, the intermediate filament protein 
vimentin, was shown recently to be phosphorylated by Akt1 (58). 
Akt1-mediated vimentin phosphorylation promotes migration and 
invasion of soft-tissue sarcoma cells. As summarized above, for sev-
eral cytoskeleton-associated proteins that were recently identified 
as Akt substrates, such as Girdin, Kank, and Filamin, it is not known 
so far whether they are selectively phosphorylated by individual Akt 
isoforms. However, it should be noted that the kinase domains of 
all three isoforms are highly conserved and many of the known Akt 
substrates may be indiscriminately phosphorylated by all isoforms. 
Therefore, apart from the isoform-specific substrates, Akt isoform–
regulated cell motility may be mediated by isoform-specific inter-
action proteins (4). It is conceivable that the selectivity of substrates 
is due to sequence-determined specific interactions and that it is 
actually this interaction that plays the crucial role. To test this, it 
would be important to use nonphosphorylatable substrates that are 
nevertheless able to bind Akt to interfere with the phosphorylation 
process. Given the relatively clear phenotypes of the transgenic 
mouse models, ideally catalytically inactive or binding-deficient 
Akt mutants could be used to try to rescue these phenotypes, espe-
cially in models in which Akt isoforms are genetically deleted.
In summary, extensive evidence suggests that Akt-transduced 
signals directly influence cell motility in normal development and 
in disease. An increasing number of “good drugs do bad things” 
have been reported in the clinic. For example, the BRAFV600E inhib-
itors mistakenly also target another RAF isoform, CRAF, and unfa-
vorably create more malignant phenotypes in melanoma (124,125). 
Therefore, it is worth paying extra attention to the performance of 
the many Akt inhibitors being tested in preclinical trials. Several 
such inhibitors have been shown to attenuate cancer cell invasion 
(126,127), and it is, therefore, important to test whether they exhibit 
priorities in targeting individual Akt isoforms. This approach arises 
from recent advances in the field showing that the three highly 
homologous Akt isoforms have nonoverlapping activities and even 
exert opposing effects in different cancer types. Thus, given that 
metastasis causes 90% of death of cancer patients (128) and Akt 
is the major signaling node that integrates membrane, cytoplas-
mic, and nuclear signals determining cell fate, dissection of Akt 
isoform–specific signaling pathways to gain more insight into the 
identified Akt downstream substrates that affect cell motility will 
contribute to targeted cancer therapies in the clinic.
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